Nexstim sells first NBT® system in Germany for depression therapy and research

- 22/05/2019

Helsinki, Finland: 22 May 2019 – Nexstim Plc (NXTMH:HEX, NXTMS:STO), the targeted neuromodulation company developing and marketing pioneering navigated personalised, non-invasive brain stimulation systems for the treatment of Major Depressive Disorder (MDD), announces that it has sold an NBT® system to a leading university hospital in northern Germany.

The system will be the first Nexstim NBT® system in Germany used for the treatment of depression and for depression-related clinical research.

Nexstim NBT® systems are using a unique SmartFocusTM TMS (transcranial magnetic stimulation) technology. It is differentiated by its sophisticated 3D navigation system, based on a patient’s MRI scan, that uses its proprietary E-field algorithm to visualize the exact location, orientation and magnitude of the stimulation given to the brain to treat MDD.

More info on Nexstim’s website